CareDx, Inc (CDNA) Stock
CDNA Key Statistics
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
CEO: John Walter Hanna Jr.. Company website
CDNA — Frequently Asked Questions
What is the CDNA stock price today?
CareDx, Inc (CDNA) trades at $89.60, up 25.28% on the day, as of Nov 12, 2026 09:20 UTC.
What is CareDx, Inc's market cap?
CareDx, Inc has a market capitalisation of $4.61B, calculated from the live CDNA share price and shares outstanding.
What is the P/E ratio of CDNA?
CDNA has no meaningful price-to-earnings ratio: CareDx, Inc lost $0.40 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does CareDx, Inc make?
CareDx, Inc generated revenue of $379.81M over the trailing twelve months, which puts the stock at 12.13 times sales.
What is the 52-week range for CDNA?
CDNA has traded between $14.72 and $90.87 over the past 52 weeks, and the last price is 1.4% below that high.
Is CareDx, Inc profitable?
No. CareDx, Inc is loss-making, with a net margin of -5.62% over the trailing twelve months.
What is the analyst price target for CDNA?
Wall Street analysts rate CDNA Buy, with an average price target of $23.33, 74.0% below the current price.
What sector is CareDx, Inc in?
CareDx, Inc is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US .
Who is the CEO of CareDx, Inc?
John Walter Hanna Jr. is the chief executive of CareDx, Inc, which employs 644 people.
Where can I track CDNA in real time?
QFI Terminal shows CDNA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CDNA live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CDNA in Terminal See plans